References
- Giovanella B. C., Stehlin J. S., Wall M. E., Wani M. C., Nicholas A. W., Liu L. R, Silber R., Pomesil M. DNA Topoisomerase I-targeted chemotherapy of human colon cancer xenografts. Science 1989; 246: 1046–1048
- Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873–14878
- Hsiang Y. H., Liu L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48: 1722–1726
- Hertzberg R. P., Caranfa M. J., Hecht S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence of binding to an enxyme-DNA complex. Biochem 1989; 28: 4629–4638
- Pantazis P., Hinz H. R., Mendoza J. T., Kozielski A. S., Williams L. J., Stehlin J. S., Jr, Giovanella B. C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro, and regression of human xenografts in immunodeficient mice induced by camptoth-ecins. Cancer Res 1992; 52: 3980–3987
- Wani M. C., Nicholas A. W., Wall M. E. Plant antitumor agents: synthesis and antileukemic activity of camptothecin analogues. J Med Chem 1986; 29: 2353–2363
- Saiki N. K., Brigawan T. L., Horn G. T., Mullis K. B., Ehlich H. A. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotides probes. Nature 1986; 324: 163
- Kawasaki E. S. Sample preparation from blood, cells and other fluids. In PCR Protocols. A Guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Snishy, T. H. White. Academic, San Diego 1990; 146
- Beran M., Pisa P., Kantarjian H., Porwit A, Bjorkholm M. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol Pathol 1994; 8: 135
- Hsu H. M., Raine L., Fanger H. Use of avi-din-biotin-peroxidase techniques: a comparison between ABC and unlabeled (PAP) procedures. J Histochem Cytochem 1981; 29: 577
- Champlin R, Gale R. P. Acute myelogenous leukemia: recent advances in therapy. Blood 1987; 69: 1551–1562
- Vogler W. R., Velez-Garcia E., Weiner R. S., Flaum M. A., Bartolucci A. A., Omura G. A., Gerber M. C., Banks P. L.C. A phase III trial comparing Idarubicin and Daunorubicin in combination with Cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol 1992; 10: 1103–1111
- Jeha S., Kantarjian H., O'Brien S., Huh Y., Pisa P., Ordonez N., Beran M. Growth and biologic properties of karyotypically defined subcategories of adult acute lymphocytic leukemia in mice with severe combined immunodeficiency. Blood 1995; 86(11)4278–4285
- Cesano A., O'Connor R., Lange B., Finan J., Rovera G., Santoli D. Homing and progression patterns of childhood acute lymphoblastic leukemias in severe combined immunodeficiency mice. Blood 1991; 77: 2463
- Kamel-Reid S., Letarte M., Doedens M., Greaves A., Murdoch B., Grenberger T., Lapidot T., Thorner P., Freedman M. H., Phillips R. A., Dick J. E. Bone marrow from children in relapse with pre-B acute lymphoblastic leukemia proliferates and disseminates rapidly in SCID mice. Blood 1991; 79: 2973
- Uckun F. Severe combined immunodeficient mouse models of human leukemia. Blood 1996; 96: 1135–1146
- Beran M., Jeha S., O'Brien S., Estey E., Vitek L., Zurlo M. G., Rios M. B., Keating M. J., Kantarjian H. M. Tallimustine, an effective antileukemic agent in severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a Phase I study. Clin Cancer Res 1997; 3: 2377–2384